Journal: bioRxiv

Article Title: Targeting DNMT1 augments anti-tumor CD8⁺ T cell function

doi: 10.64898/2026.07.03.736412

Figure Lengend Snippet: (A) Timeline for tumor injection and drug treatments. Tumor cells were injected on d0. (B) Tumor growth in individual mice treated with DNMTi (RG108) alone, ICI (anti-CTLA4) alone, or dual therapy (ICI+DNMTi). (C) Overall survival of mice receiving ICI (anti-CTLA4), DNMT1i (RG108 or GSK32), or ICI+DNMT1i (RG108 or GSK32) (log-rank Mantel Cox test). (D) UMAP reduction of identified clusters from 4 treatment groups (DNMTi alone (RG108), ICI (anti-CTLA4) alone, dual therapy, and control) with 3 mice per condition and 2 tissues (tdLN and tumor) from each mouse. (E) UMAP reduction of total CD8+ T cells from tdLN from all 4 treatment groups. (F) Dot plot showing expression of key markers defining each CD8 cluster. (G) UMAP reduction of total CD8+ T cells from tdLN from all 4 treatment groups using Monocle3 for trajectory analysis and (H) trajectory analysis colored by pseudotime. (I) Pseudobulk quantification of the proportion of CD8⁺ T cells in the naïve-like cluster (left) and T PEX cluster (right) (n=3).

Article Snippet: On day 7, live CD8+ T cells were enriched using a dead-cell removal kit (Miltenyi) and added to tumor cells at a 1:10 T-cell:tumor ratio.

Techniques: Injection, Control, Expressing

Journal: bioRxiv

Article Title: Targeting DNMT1 augments anti-tumor CD8⁺ T cell function

doi: 10.64898/2026.07.03.736412

Figure Lengend Snippet: (A) Schematic of in vitro primary P14 CD8+ T cell culture model. (B) Schematic describing abbreviated nomenclature for in vitro cell states (T M , T EX , T EX+D , T M* , T EX* , T EX+D* ). (C) P14 CD8⁺ T cells were isolated on d7 of culture and restimulated with gp33 peptide for flow cytometry analysis of IFNγ and TNFα production (left) or co-cultured with gp33-expressing mouse melanoma line YUMM-G1-gp33 to assess tumor cell killing (right) by flow cytometry (n=3). (D) Chronic stimulation promotes proliferation of CD8+ T cells as shown by CellTrace Violet dilution (left) and quantified as proportion of cells in each generation (right) (n=3). (E-F) Violin plots showing differentially expressed genes between T EX+D and T EX (E) and between T EX+D* and T EX* (F) with RG108 (left) or with GSK32 (right). An adjusted p-value cutoff of 0.05 and log2FC cutoff of 0.5 were used. (G) UMAP depicting clusters obtained using PhenoGraph for concatenated samples (top left) and density plots for TEX* (top right), TEX+D* (GSK-32) (bottom left), and TEX+D* (RG108). (H) Proportion of live, CD45+ cells in MC4 (left) and MC14 (right) across samples. (I) Heatmap representing the relative expression of markers across clusters. (J) Schematic showing consensus nonnegative matrix factorization (cNMF) matrices. (K) Gene by program matrix from cNMF showing loadings for genes in the top 150 ranked gene list for each module. (L) Comparison of T EX vs T EX+D usage of Program S (left) and Program E1(right). (M) Comparison of T EX vs T EX+D usage of Program E2 (left) and Program E3 (right). (N) Comparison of T EX* vs T EX+D* usage of Program E1 (left) and Program E3 (right).

Article Snippet: On day 7, live CD8+ T cells were enriched using a dead-cell removal kit (Miltenyi) and added to tumor cells at a 1:10 T-cell:tumor ratio.

Techniques: In Vitro, Cell Culture, Isolation, Flow Cytometry, Expressing, Comparison